Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 2,001–2,100 of 4,108
Reviewing acute hip fractures in adults
Barry, M. L., & Maday, K. R. (2021) · JAAPA · doi:10.1097/01.jaa.0000742968.43332.6e · Cited by 9
Bovine Colostrum Supplementation Improves Bone Metabolism in an Osteoporosis-Induced Animal Model
Kydonaki, E. K., Freitas, L., Fonseca, B. M., Reguengo, H., Simón, C. R., Bastos, A. R., Fernandes, E. M., Canadas, R. F., Oliveira, J. M., Correlo, V. M., et al. (2021) · Nutrients · doi:10.3390/nu13092981 · Cited by 8
“Non-pharmacological management of osteoporosis includes the maintenance of sufficient vitamin D and calcium concentrations [20,21].”
BackgroundZhang, R., Yan, K. H., Wu, Y., Yao, X., Li, G., Ge, L., & Chen, Z. (2021) · Clinical Proteomics · doi:10.1186/s12014-021-09330-0 · Cited by 10
Pathak, S., Vyas, S. P., & Pandey, A. (2021) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2021v13i6.42697 · Cited by 8
Vitamin A and its dervatives effect on bone mineral density, a systematic review
Khojah, Q., AlRumaihi, S., AlRajeh, G., et al. (2021) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_663_21 · Cited by 8
“The outcomes including osteoporosis (a common skeletal disorder characterized by decreased bone density, compromised bone strength, and increased fracture risk[14]) were based on the BMD measures for the two groups, exposed and nonexposed.”
BackgroundGuo, R., Li, B., Zeng, Z., et al. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-6285 · Cited by 8
“21037/atm-21-6285 Introduction Osteoporosis is the most common metabolic bone disease in the elderly, which can lead to bone loss and fragility fractures (1).”
BackgroundArsan, B. (2022) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2022.02.008 · Cited by 8
Harahap, I. A., & Suliburska, J. (2022) · Materials Today Proceedings · doi:10.1016/j.matpr.2022.03.549 · Cited by 10
Konstantelos, N., Rzepka, A. M., Burden, A. M., Cheung, A. M., Kim, S., Grootendorst, P. V., & Cadarette, S. M. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06395-x · Cited by 8
Osteoporosis management in the United States
Hoggard, T. M., & Jeray, K. J. (2022) · OTA International The Open Access Journal of Orthopaedic Trauma · doi:10.1097/oi9.0000000000000184 · Cited by 9
“has also put forth a series of clinician guidelines with detailed recommendations regarding specific indications for diagnostic assessment tools, pharmacological treatment, and monitoring protocols.([3]) These guidelines also outline appropriate use of BMD testing and diagnostic vertebral imaging, as well as indicatio…”
BackgroundRoss, B. J., Ross, A. J., Lee, O. C., Waters, T. L., Familia, M. M., & Sherman, W. F. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06451-6 · Cited by 8
“Low rates of DEXA evaluation are incongruent with the known association between MS and osteoporosis as well as earlier osteoporosis detection and treatment leading to decreased fracture risk [2, 53].”
BackgroundInfluentialBeck, D., Winzenborg, I., Gao, W., Mostafa, N. M., Chiuve, S. E., Owens, C. D., & Shebley, M. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15440 · Cited by 7
“Based on the simulated patient-level longitudinal data, the age when a particular patient reached the riskbased threshold for anti-osteoporosis treatment was defined as the earliest age when the patient reached a 10-year risk of hip fractures ≥3% or a 10-year risk of MOF ≥20%.(25,34) The median difference in FN-BMD, 1…”
MethodYe, H., Li, X., Yao, N., Shi, Y., Wang, Y., & Yu, W. (2022) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-22-72 · Cited by 7
“The BMD is considered an important indicator for monitoring osteoporosis and estimating fracture risk, especially for women and the elderly (2,3).”
Effect of Discordant Hip Bone Density on Incident Fracture Risk: A Registry-Based Cohort Study
Leslie, W. D., Morin, S. N., Lix, L. M., McCloskey, E. V., Johansson, H., Harvey, N. C., & Kanis, J. А. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4672 · Cited by 9
“The FRAX tool considers multiple clinical risk factors in addition to BMD at the femoral neck and has been adopted by multiple guidelines.((4-7)) Although designation of the femoral neck as the reference site”
MethodThe Impact of Osteoporosis on 2-Year Outcomes in Patients Undergoing Long Cervical Fusion
Diebo, B. G., Scheer, R. C., Rompala, A., Veenema, R. J., Shah, N. V., Beyer, G. A., Çeliker, P., Eldib, H., Passfall, L., Krol, O., et al. (2022) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-22-00361 · Cited by 9
Elmas, H., Duran, C., Can, M., Tolu, İ., & Güney, İ. (2023) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1055/s-0043-1764497 · Cited by 11
Considerations regarding adherence of anti-osteoporosis therapy
Lagari, V. S., McAninch, E. A., & Baim, S. (2014) · Postgraduate Medicine · doi:10.1080/00325481.2015.993278 · Cited by 10
Osteoporosis's Menopausal Epidemiological Risk Observation (O.M.E.R.O.) study
Lello, S., Sorge, R. P., Surico, N., & OMERO Study Group (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1063605 · Cited by 8
Cho, I.-J., Chung, H.-Y., Kim, S.-W., Lee, J., Lee, T.-W., Kim, H.-S., Kim, S. G., Choi, H. S., Choi, S. H., Shin, C. S., et al. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.3.272 · Cited by 8
Fracture risk assessment in postmenopausal women
Hamdy, R. C. (2009) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-009-9118-4 · Cited by 11
Markopoulos, C. J., Tzoracoleftherakis, E., Koukouras, D., Venizelos, B., Zobolas, V., Misitzis, J., Xepapadakis, G., & Gogas, H. J. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1233-z · Cited by 8
Lin, T., Yang, C.-Y., Yang, Y. K., & Lin, S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1877 · Cited by 10
Protection of bone in premenopausal women with breast cancer: focus on zoledronic acid
Aft, R. (2012) · International Journal of Women s Health · doi:10.2147/ijwh.s29101 · Cited by 8
Zhang, J., Delzell, E., Curtis, J. R., Hooven, F. H., Gehlbach, S. H., Anderson, F. A., & Saag, K. G. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2444-0 · Cited by 8
Menopause-related osteoporosis
Snyman, L. C. (2014) · South African Family Practice · doi:10.1080/20786204.2014.932549 · Cited by 9
Naegeli, A. N., Nixon, A., Burge, R. T., Gold, D. T., & Silverman, S. L. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2448-9 · Cited by 11
Multidisciplinary osteoporosis management of post low‐energy trauma hip‐fracture patients
Skorupski, N., & Alexander, I. M. (2012) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/1745-7599.12002 · Cited by 8
Nogués, X., Rentero, M. L., & Rodríguez, A. L. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.851659 · Cited by 8
Parathyroid Hormone Secretion and Action
Isaia, G., Marchese, L., Marchetti, M., D’Amelio, P., & Fornelli, G. (2015) · Updates in surgery/Updates in surgery series · doi:10.1007/978-88-470-5758-6_3 · Cited by 8
Recognition and Treatment of Postmenopausal Osteoporosis
Hannafon, F., & Cadogan, M. P. (2014) · Journal of Gerontological Nursing · doi:10.3928/00989134-20140204-01 · Cited by 10
McDonald, A. M., Jones, J. A., Cardan, R., et al. (2016) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2016.04.011 · Cited by 9
Prevalence of Low Bone Mineral Density and Associated Risk Factors in Korean Puerperal Women
Jang, D. G., Kwon, J. Y., Choi, S. K., Ko, H. S., Shin, J. C., & Park, I. Y. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2016.31.11.1790 · Cited by 8
ANTIOSTEOPOROTIC ACTIVITY OF ANTHRAQUINONE ISOLATED FROM MORINDA CITRIFOLIA FRUITS IN RATS
Joy, A., Chaitra, N., Ashok, M., et al. (2016) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2016.v9i5.13269 · Cited by 8
Angeles‐Agdeppa, I., Magsadia, C., AARON, G. A., Lloyd, B. B., Hilmers, D. C., & Bhutta, Z. A. (2017) · Nutrients · doi:10.3390/nu9091002 · Cited by 13
Saltzman, W., Abbott, D. H., Binkley, N., & Colman, R. J. (2018) · American Journal of Primatology · doi:10.1002/ajp.22905 · Cited by 8
Wang, C., Fu, S., Huang, C., Hung, C., Yang, R., & Hsiao, F. (2018) · International Journal of Clinical Practice · doi:10.1111/ijcp.13246 · Cited by 8
Hettiarachchi, M., Cooke, R., Norton, C., & Jakeman, P. M. (2019) · Nutrients · doi:10.3390/nu11061413 · Cited by 9
Wang, C., Liu, J., Xiao, L., Liu, D., Yan, W., Hu, T., Li, K., Hua, X., & Zeng, X. (2019) · Journal of International Medical Research · doi:10.1177/0300060519879591 · Cited by 8
Dynamic Change of Lumbar Structure and Associated Factors: A Retrospective Study
Wei, J., Zhu, Y., Zhao, D., et al. (2019) · Orthopaedic Surgery · doi:10.1111/os.12557 · Cited by 8
LncRNA AWPPH is downregulated in osteoporosis and regulates type I collagen α1 and α2 ratio
Qian, G., Yu, Y., Dong, Y., Hong, Y., & Wang, M. (2020) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2020.1767150 · Cited by 8
Panahi, N., Ostovar, A., Fahimfar, N., Meybodi, H. R. A., Gharibzadeh, S., Arjmand, B., Sanjari, M., Khalagi, K., Heshmat, R., Nabipour, I., et al. (2021) · BMC Geriatrics · doi:10.1186/s12877-021-02375-8 · Cited by 8
Yang, H., Cui, X., Zheng, X., et al. (2021) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2021.09.008 · Cited by 8
Chang, Y., Chang, C., Wang, M.-W., Wu, C.-F., Chen, C., Chang, H.-J., Kuo, P., & Wu, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161773 · Cited by 10
Low calcium and vitamin D intake in Korean women over 50 years of age
Lee, Y., Chang, J. S., Min, Y., Byun, D. W., Park, Y., & Ha, Y. (2016) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-016-0782-7 · Cited by 9
Ou, L.-C., Chang, Y., Chang, C., Chiu, C., Chao, T., Sun, Z., Lin, R.-M., & Wu, C. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013420 · Cited by 7
Osteoporosis in males and its association with tobacco; smokers and chewers
Abbas, S. S., Baig, S., Jamal, Q., Danish, H., & Amber, S. A. (2015) · European Journal of Biotechnology and Bioscience · Cited by 10
Fitzgerald, G. E., O’Dwyer, T., Mockler, D., O'Shea, F. D., & Wilson, F. (2020) · Rheumatology International · doi:10.1007/s00296-020-04623-3 · Cited by 9
Relationship Between BMD and Prevalent Vertebral Fractures in Indian Women Older Than 50 Yr
Gupta, Y., Marwaha, R. K., Kukreja, S. C., Bhadra, K., Narang, A., Mani, K., Mithal, A., & Tandon, N. (2015) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2015.04.007 · Cited by 8
Setty, N. V. N., LeBoff, M. S., Thornhill, T. S., et al. (2011) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2011.06.001 · Cited by 8
Self-citationOsteoporosis: Treatment Gaps and Health Economics
Harvey, N. C., McCloskey, E. V., Rizzoli, R., Kanis, J. А., Cooper, C. C., & Reginster, J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99202-x · Cited by 10
Prognostic factors and prediction model for 1-year mortality after proximal humeral fracture
Grootven, B. V., Janssens, S., Keyser, L. D., et al. (2023) · Archives of Osteoporosis · doi:10.1007/s11657-023-01260-8 · Cited by 7
“Osteoporosis is a systemic skeletal disease characterised by a low bone mass and deterioration of the bone micro-architecture [3].”
Effect of educational intervention on preventing osteoporosis in postmenopausal women
Najafi, S., Mohammadkhah, F., Ebrahimi, M. M., Harsini, P. A., & Jeihooni, A. K. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06962-w · Cited by 11
“…at or below −2.5) are included in osteoporosis classification, and 2.5 SD or more below that of the mean level for a young-adult reference population with fractures BMD (T-score at or below −2.5 with one or more fractures) are included in severe or established osteoporosis classification [12].”
InfluentialUsing sequential pharmacotherapy for the treatment of osteoporosis: an update of the literature
Mondo, I., Hannou, S., & D’Amelio, P. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2296543 · Cited by 10
“Among Caucasian adults aged 50 years and over living in the U.S.A., 50% of women and 20% of men will experience an osteoporotic fracture in their lifetime [2].”
BackgroundSecondary fracture prevention in Spanish primary care: results of the PREFRAOS Study
Martínez-Laguna, D., Carbonell-Abella, C., Bastida, J.-C., González, M., Micó-Pérez, R. M., Vargas, F., Torres, E. D., Canals, L., & on behalf of the PREFRAOS Group (2024) · Archives of Osteoporosis · doi:10.1007/s11657-024-01394-3 · Cited by 7
Lee, J., Kim, J., Kim, Y., Kim, Y.-S., Kim, J., & Kang, H. (2024) · The Spine Journal · doi:10.1016/j.spinee.2024.05.003 · Cited by 10
Szyszko, J. A., Aldieri, A., Mattina, A. A. L., & Viceconti, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305474 · Cited by 9
Gou, Y., Xie, X., Yin, H., Wu, Y., Wen, Y., & Zhang, Y. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.70047 · Cited by 7
Yuntao, L., Haibier, A., Kayierhan, A., et al. (2025) · BMC Surgery · doi:10.1186/s12893-025-02820-0 · Cited by 7
“Patients are generally older, and due to slow fracture healing, poor quality of life, and other reasons, various complications may occur, increasing the risk of disability and death, and imposing a heavy economic burden on patients’ families [6, 7].”
Yang, R., Huang, Z., Shao, S., et al. (2025) · World Neurosurgery · doi:10.1016/j.wneu.2025.123911 · Cited by 7
Cappola, A. R., Abraham, D. S., Kroopnick, J. M., Huang, Y., Hochberg, M., Miller, R. R., Shardell, M. D., Hicks, G. E., Orwig, D., & Magaziner, J. S. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07446-9 · Cited by 9
Wang, Z., Wang, W. J., Wang, Y., Hu, H., Wang, B., Zhu, W., Li, X., Hou, X., Sun, W., Liu, Z., et al. (2025) · European journal of medical research · doi:10.1186/s40001-025-02795-x · Cited by 12
Schmorl's nodes: A clinical clue for disguised osteoporosis
Çulha, B., Abacıoğlu, H. B., & Kara, M. (2025) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.70158 · Cited by 7
Ena, G., & Soyfoo, M. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010102 · Cited by 10
“Low body weight (BMI below 20 kg/m 2 ) and evidence of frailty or sarcopenia may indicate increased fracture risk [20].”
Diagnosis and Management of Osteoporotic Vertebral Compression Fractures
Daher, M., Sebaaly, A., Sakr, I., Daniels, A. H., & Schoenfeld, A. J. (2025) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.25.00201 · Cited by 11
Gámez-Nava, J. I., Muñiz, S. A. Z., Vazquez-Villegas, M. L., VEGA-LOPEZ, A., Rodriguez-Jimenez, N. A., Olivas-Flores, E. M., Gonzalez-Montoya, N. G., Corona-Sánchez, E. G., Rocha-Muñoz, A. D., Martinez-Corral, M. E., et al. (2012) · Rheumatology International · doi:10.1007/s00296-011-2341-9 · Cited by 7
Abaloparatide and the Spine: A Narrative Review
Thompson, J. C., Wanderman, N., Anderson, P. A., & Freedman, B. A. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s227611 · Cited by 9
Approach to Managing a Postmenopausal Patient
Santen, R. J., Heitjan, D. F., Gompel, A., Lumsden, M. A., Pinkerton, J. V., Davis, S. R., & Stuenkel, C. A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa623 · Cited by 9
An Overview of Osteoporosis Management
Jiang, N. S., Newton, B., & Jiang, X. (2021) · OBM Geriatrics · doi:10.21926/obm.geriatr.2104181 · Cited by 8
Future Fracture Risk in Upper Extremity Fracture and Non-Fracture Patients
Seyok, T., Collins, J. E., Erikson, S. J., et al. (2022) · Hand · doi:10.1177/15589447211049521 · Cited by 7
Langsetmo, L., Schousboe, J. T., Taylor, B. C., Cauley, J. A., Fink, H. A., Cawthon, P. M., Stefanick, M. L., Kado, D. M., Kats, A. M., & Ensrud, K. E. (2022) · The Journals of Gerontology Series A · doi:10.1093/gerona/glac159 · Cited by 7
Aflatooni, J. O., Martin, S. E., Edilbi, A., Gadangi, P., Singer, W., Loving, R., Domakonda, S., Solanki, N., McCulloch, P. C., & Lambert, B. S. (2023) · Sports Medicine and Health Science · doi:10.1016/j.smhs.2023.09.003 · Cited by 8
The role of the fracture liaison service in the prevention of atypical femoral fractures
Toro, G., Braile, A., Liguori, S., Moretti, A., Landi, G., Cecere, A. B., Conza, G., Cicco, A. D., Tarantino, U., & Iolascon, G. (2023) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x231212747 · Cited by 10
Argeșanu, R. D., Brîndușe, L. A., Mogoș, C. I., Bratu, E. C., Armean, P., & Cucu, M. A. (2023) · Balneo and PRM Research Journal · doi:10.12680/balneo.2023.634 · Cited by 8
Lei, C., Wu, X., Wang, S., et al. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.103728 · Cited by 7
Guthrie, B., Rogers, G., Livingstone, S. J., Morales, D. R., Donnan, P. T., Davis, S., Youn, J.-H., Hainsworth, R., Thompson, A., & Payne, K. (2024) · Health and Social Care Delivery Research · doi:10.3310/kltr7714 · Cited by 11
Osteoporosis and Primary Biliary Cholangitis: A Trans-ethnic Mendelian Randomization Analysis
Wu, Y., Qian, Q., Liu, Q., Wang, R., Pu, X., Li, Y. O., Zhang, H., You, Z., Miao, Q., Xiao, X., et al. (2024) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-024-08986-4 · Cited by 10
Lima, D. P., das Chagas-Neto, F. A., de Luna, J. R. G., Martins, Y. D. O., de Almeida, S. B., Feitosa, C. X., Gradvohl, L. B., Rosa, I. D., Lopes, F. K. D. M., Aragão, L. F. F., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1326212 · Cited by 11
“…postmenopausal women and men aged 50 years or older, the National Osteoporosis Foundation (NOF) proposed the use of the FRAX algorithm (Fracture Risk Assessment Tool) to assess the risk of osteoporosis and fracture aiming to determine the need for BMD testing, spinal imaging and treatment (6) (7).”
BackgroundMethodInfluentialKale, A., Khandelwal, N., Sirohi, B., Shaki, O., & Rai, S. (2024) · Cureus · doi:10.7759/cureus.59606 · Cited by 17
Liu, J., Jiang, J., Li, Y., Chen, Q., Yang, T., Lei, Y., He, Z., Wang, X., Na, Q., Lao, C., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1439255 · Cited by 11
“The most common fractures are vertebrae (spine), proximal femur (hip), and distal forearm (wrist), whicharealsooneofthemainfactorscontributingtotheincreasedrisk of death in the affected population (6).”
BackgroundCurrent status and dilemmas of osteoporosis screening tools: A narrative review
Zhang, Y., Ma, M., Tian, C., Liu, J., Huang, X., Duan, Z., Zhang, X., Sun, S., Zhang, Q., & Geng, B. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.10.001 · Cited by 8
Agostini, F., Alessandro de, S. I. R. E., Sveva, V., Finamore, N., Savina, A., Fisicaro, A., Bernetti, A., Santilli, V., Mangone, M., & Paoloni, M. (2024) · Disability and Rehabilitation · doi:10.1080/09638288.2024.2440142 · Cited by 10
Targeted assessment of fracture risk in women at midlife
Davis, S. R., Tan, A., & Bell, R. J. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3046-9 · Cited by 7
Wang, C., Wu, C., & Farley, J. F. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015588127 · Cited by 7
Fracture Risk Assessment in Diabetes
Leslie, W. D., & Hough, S. F. (2015) · Springer eBooks · doi:10.1007/978-3-319-16402-1_3 · Cited by 11
Man, Y., Pan, W. R., Lu, J., Li, S., Zhang, P., Guo, J., Yu, S., Zhang, B., Xiao, E., Zhang, C., et al. (2016) · Orthopaedic Surgery · doi:10.1111/os.12296 · Cited by 7
Yeap, S. S., Hew, F. L., Damodaran, P., Chee, W. S. S., Lee, J. K., Goh, E. M. L., & Chan, S. P. (2017) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2017.01.001 · Cited by 7
Zysset, P. K., & Wolfram, U. (2017) · Journal of the mechanical behavior of biomedical materials/Journal of mechanical behavior of biomedical materials · doi:10.1016/j.jmbbm.2017.07.008 · Cited by 7
Taşçı, İ., Cintosun, Ü., Safer, U., Naharcı, M. İ., Bozoğlu, E., Aydoğdu, A., & Doruk, H. (2017) · Acta Clinica Belgica · doi:10.1080/17843286.2017.1412863 · Cited by 7
Lin, F.-C., Wang, C., Shang, R.-J., Hsiao, F., Lin, M., Hung, K., Wang, J., Lin, Z., Lai, F., Shen, L., et al. (2018) · Journal of Medical Internet Research · doi:10.2196/jmir.9477 · Cited by 7
Marcela Barberán, M., Claudia Campusano, M., Trincado, P., Sofía Oviedo, G., Sergio Brantes, G., Jorge Sapunar, Z., Canessa, J., Cid, P., Escobar, F., Eugenin, D., et al. (2018) · Revista médica de Chile · doi:10.4067/s0034-98872018001201471 · Cited by 14
Weaver, F. M., Le, B. K., Ray, C. E., Miskevics, S. A., González, B., & Carbone, L. D. (2019) · Journal of Spinal Cord Medicine · doi:10.1080/10790268.2019.1584259 · Cited by 8
Estimating Waist and Hip Circumference from Routine Clinical DXA
Leslie, W. D. (2019) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2019.08.001 · Cited by 7
Spinal Posture and Pathology in Modern Humans
Been, E., Simonovich, A., & Kalichman, L. (2019) · Springer eBooks · doi:10.1007/978-3-030-19349-2_13 · Cited by 7
Lessons learned with Bone Health TeleECHO: making treatment decisions when guidelines conflict
Rothman, M. S., Olenginski, T. P., Stanciu, I., Krohn, K., & Lewiecki, E. M. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05147-8 · Cited by 8
Self-citationHong, L., Ai, J., & Ma, D. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.07.091 · Cited by 7
Office-Based Kyphoplasty: A Viable Option Using Local Anesthesia with Oral Sedation
Chandler, G. (2019) · Pain Physician · doi:10.36076/ppj/2019.22.177 · Cited by 7
Leslie, W. D., Morin, S. N., Lix, L. M., & Binkley, N. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-00763-y · Cited by 8
Understanding Osteoporosis Screening Practices in Men: A Nationwide Physician Survey
Choksi, P. U., Gay, B. L., Reyes‐Gastelum, D., Haymart, M. R., & Papaleontiou, M. (2020) · Endocrine Practice · doi:10.4158/ep-2020-0123 · Cited by 8
“In regards to guidelines, physicians were asked to state whether they had read any of the following guidelines: 2008 Screening for Osteoporosis in Men: A Clinical Practice Guideline from the American College of Physicians (19); 2008 National Osteoporosis Foundation Clinical Practice Guidelines (20); 2012 Osteoporosis…”
BackgroundMethodYu, W., Zhang, Z., Pan, W. R., Guan, W., Lin, Q., Xia, W., Li, T., & Hsieh, E. (2021) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2021.01.003 · Cited by 9
Integrative Analyses of Genes Associated With Osteoporosis in CD16+ Monocyte
Hu, B., Kong, X., Li, L., Dai, F., Zhang, Q., & Shi, R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.581878 · Cited by 9
“Osteoporosis is a metabolic bone disease that causes bone mass loss and fragility fracture (1).”
Background
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.